Meet Rejoovenate Bio Online Webinar
Join us for an online webinar to meet one of the AthenaBIO-supported start-ups, Rejoovenate Bio!
📆 Date: Thursday, May 14th, 2026
⏰ Time: 12:00 PM ET
📍 Location: Online
About AthenaBIO
AthenaBIO is the leading decentralized collective working on transformative women’s health R&D funding, education, and access.
We collaborate with leading academics and research institutes; have funded research at University of Colorado, Cornell University, the National University of Singapore, and others; published five Reproductive Health Reports; and have a global network of over 35k members.
Are you interested in becoming a member? You can sign up here! 🧬🪩
Check out our Linktree to learn more: 💁♀️ https://linktr.ee/athenadao
About Rejoovenate Bio
Rejoovenate Bio is a fertility biotech company focused on addressing age-related declines in egg quality. Rejoovenate is developing laboratory-based solutions designed to improve reproductive outcomes by targeting the underlying biology of reproductive aging without systemic exposure. Their approach is built to integrate seamlessly into existing IVF workflows, enabling fertility clinics to offer more effective options for patients of advanced maternal age.
The founding team features Dr. Iris Lam and Dr. Manju Sharma:
Iris Lam, PhD, is a repeat VC-backed founder with 8+ years in cell and molecular biology, completing a Doctorate in Medical Science in 2026. Ex. Max Planck, Charité Berlin, and DukeNUS Medical School.
Manju Sharma, PhD, is a biologist specializes in germ stem cell development, reproductive aging, fertility and regenerative medicine. Known for translating complex biological insights into therapeutic innovation. Her research has uncovered key regulators of germ stem cell self‑renewal, identified mechanisms underlying age‑related infertility, and advanced epigenetic reprogramming strategies to restore tissue function. At Stanford, she investigated partial reprogramming technologies to reverse cellular aging, with a focus on rejuvenating female reproductive tissues and understanding how ovarian epigenetic states influence the hypothalamic–pituitary axis and overall reproductive health. With extensive experience in transgenic mouse models, multi‑omics, and assay development, she has driven multi‑year programs from concept to preclinical validation and contributed to patented technologies in wound healing and hair regeneration.